ARHGAP32

Across TCGA pan-cancer cohorts, ARHGAP32 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of ARHGAP32’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ARHGAP32 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ARHGAP32 is over-expressed in tumor, although a few such as HNSC and PDAC show the opposite, repressed pattern.

HNSC, LSCC, and PDAC are the cancer types where ARHGAP32 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARHGAP32 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	−0.508	<.001	8	view →
LSCC	All	II,III,IV	+0.244	<.001	8	view →
PDAC	All	All	−0.217	.006	4	view →
LUAD	Female	All	+0.181	.001	4	view →
COAD	Male	III,IV	+0.412	.040	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

ARHGAP32–HNSC

Open the HNSC breakdown →